Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2018-12-12 Regulatory Filings
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Settlement Negotiations 1 page 231.0KB
Regulatory Filings Classification · 95% confidence The document is a short announcement from Phosphagenics Limited regarding ongoing settlement negotiations with Mylan and the company's trading suspension until finalisation of agreements. It does not contain financial statements, detailed financial data, or comprehensive report content. The length is only 1823 characters, which is quite short and consistent with an announcement rather than a full report. There is no indication of this being an earnings release, annual report, or any detailed financial or management report. It is a regulatory announcement about a legal/commercial negotiation status and trading suspension. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-12-12 English
Suspension from Official Quotation 2 pages 638.1KB
Regulatory Filings Classification · 95% confidence The document is a market announcement regarding the voluntary suspension of trading of Phosphagenics Limited's shares on the ASX. It references Listing Rule 17.2 and explains the suspension is pending a material announcement related to arbitration cost negotiations with Mylan. The document is short (2901 characters) and does not contain financial statements or detailed financial data. It is an announcement about a trading suspension, not a financial report or detailed disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and compliance documents that do not fit other specific categories.
2018-12-11 English
Trading Halt 2 pages 631.4KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Phosphagenics Limited regarding a trading halt requested pending a material announcement related to negotiations with Mylan. It is a short notice explaining the trading halt and the expected timing of the forthcoming announcement. There are no financial statements, detailed financial data, or report content included. The document is essentially an announcement about a trading halt and an upcoming announcement, not the announcement or report itself. Given the short length (2931 characters) and the nature of the content, this fits the criteria for a Regulatory Filing (RNS) as a general regulatory announcement rather than a full report or financial disclosure.
2018-12-09 English
Voluntary Withdrawal from OTCQX 1 page 230.7KB
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding Phosphagenics Limited's voluntary withdrawal from quotation on the OTCQX Marketplace. It includes contact information and a brief company description but does not contain any financial data, detailed report content, or regulatory filings beyond the withdrawal notice. The document length is only 1678 characters, indicating it is a brief announcement rather than a full report. There is no indication of financial statements, management discussion, or other report content. Therefore, this fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit into more specific categories.
2018-12-02 English
Receipt of R&D Tax Incentive 1 page 232.2KB
Regulatory Filings Classification · 95% confidence The document is a short announcement from Phosphagenics Limited regarding the receipt of an R&D Tax Incentive refund for the 2017-18 tax year. It does not contain any financial statements, detailed financial data, or comprehensive report content. The length is only 1576 characters, which is quite brief and typical of a regulatory or market announcement. There is no indication that this is a full annual report, interim report, earnings release, or any other detailed financial filing. It is an update on a specific financial event (receipt of tax incentive), which fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2018-11-26 English
Change in substantial holding 4 pages 1.2MB
Regulatory Filings
2018-11-22 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.